{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T05:21:25Z","timestamp":1735708885352,"version":"3.32.0"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Limited evidence exists describing the relationship between the development of atypical hemolytic uremic syndrome (aHUS) and the administration of dinutuximab. This case report describes a 20-year-old male with neuroblastoma who experienced aHUS post-dinutuximab administration. The patient presented with uncontrolled hypertension and renal dysfunction, ultimately receiving a definitive diagnosis of aHUS through a renal biopsy. The patient required complement-directed therapy with eculizmab and later transitioned to ravulizumab. This case further describes a sequential relationship between dinutuximab administration and aHUS development.<\/jats:p>","DOI":"10.1097\/mph.0000000000002966","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T13:00:10Z","timestamp":1731416410000},"page":"e68-e70","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Case Report of Dinutuximab-induced Atypical Hemolytic Uremic Syndrome"],"prefix":"10.1097","volume":"47","author":[{"given":"Letha","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pediatric Pharmacy Advent Health for Children"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3583-7655","authenticated-orcid":false,"given":"Danielle","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pharmacy Advent Health for Children"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad","family":"Hajjar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Advent Health for Children, Orlando, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"R1-20241231","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1148\/rg.2018170132","article-title":"Updates in diagnosis, management, and treatment of neuroblastoma","volume":"38","author":"Swift","year":"2018","journal-title":"Radiographics"},{"key":"R2-20241231","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"key":"R3-20241231","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Children\u2019s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-20241231","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"R7-20241231","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40272-022-00555-6","article-title":"Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future","volume":"25","author":"Gurevich","year":"2023","journal-title":"Paediatr Drugs"},{"key":"R8-20241231","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2147\/CCID.S259048","article-title":"Isotretinoin and the kidney: opportunities and threats","volume":"13","author":"Forouzani-Haghighi","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R9-20241231","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00467-004-1775-7","article-title":"Retinoic acid may increase the risk of bone marrow transplant nephropathy","volume":"20","author":"Haysom","year":"2005","journal-title":"Pediatr Nephrol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:23:25Z","timestamp":1735658605000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002966","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"type":"print","value":"1077-4114"},{"type":"electronic","value":"1536-3678"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"2024-01-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}